The Feasibility and Safety of Surgery in Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Study
Alexandra W. Elias(WinnMed), Sanjay P. Bagaria(WinnMed), Richard W. Joseph(Daiichi Sankyo (United States)), David D. Thiel(WinnMed), Dorin Colibaseanu(Mayo Clinic in Florida), Pashtoon Murtaza Kasi(Cornell University), Kabir Mody(Mayo Clinic in Florida), John Stauffer(California Institute of Technology)
Cited by 68
Related Papers
Colorectal cancer
|The Lancet|2019|5k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k